多西他赛联合顺铂治疗晚期非小细胞肺癌临床观察

目的探讨多西他赛联合顺铂治疗晚期非小细胞肺癌的临床疗效和不良反应。方法选择阜阳市人民医院收治的晚期非小细胞肺癌患者36例,所有患者第1天均给予多西他赛75 mg/m2,静脉滴注3 h,第2～5天给予顺铂20 mg/m2,静脉滴注,21 d为1个周期,化疗2个周期以上,然后按WHO标准评价疗效和不良反应。结果 36例患者均可评价疗效,全组无CR,PR 16例,SD 15例,PD 5例,总有效率(CR+PR)为44.4%。初治组有效率为54.5%,复治组有效率为28.6%,两组间比较差异有统计学意义(P<0.05)。主要的不良反应为骨髓抑制,肌肉酸痛,恶心、呕吐,脱发等,其中白细胞下降发生率为63.9%,肌肉酸痛发生率为41.6%,恶心、呕吐发生率为47.2%,脱发发生率为61.1%,患者均可耐受。结论多西他赛联合顺铂治疗晚期非小细胞肺癌有较好疗效,不良反应轻,值得临床进一步推广应用。

Clinical Observation of TAXOTERE(docetaxel) and Cisplatin(DDP) in the Treatment of Advanced Non-small Cell Lung Cancer(NSCLC)

Objective To study the efficacy and toxicity of TAXOTERE(docetaxel) and cisplatin(DDP) in the treatment of advanced non-small cell lung cancer(NSCLC).Methods A total 36 cases with advanced non-small cell lung cancer were enrolled in the study.The chemotherapy regimen consisted of TXT 75 mg/m2 by intravenous infusion for 3 hours on day 1,DDP 20 mg/m2 by intravenous infusion on day 2 to day 5.The patients were repeatedly treated every 21 days.The efficacy and toxicity were evaluated by standard of WHO more than 1 cycles later.Results All 36 cases were available for objective response,with CR 0 case,PR 16 cases,SD 15 cases,PD 5 cases.The overall response rate(CR+PR) was 44.4%.The response rate was 54.5% in the initial patients,and 28.6% in the retreated patients.The significant difference existed between the two groups(P<0.05),the main toxicities were bone marrow depression,muscular soreness and nausea/vomiting.The rate of bone marrow was 63.9%,and muscular soreness 41.6%,nausea/vomiting 47.2%,alopecia 61.1%.The adverse effects were tolerable.Conclusion The regimen of docetaxel and cisplatin was active in treating patients with advanced non-small cell lung cancer,and with mild effects.Further clinical use should be popularized.